Sign Up to like & get
recommendations!
0
Published in 2020 at "Nature Communications"
DOI: 10.1038/s41467-019-14122-0
Abstract: Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to symptoms…
read more here.
Keywords:
density marker;
sv2a reduced;
reduced schizophrenia;
sv2a ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2020 at "Schizophrenia Bulletin"
DOI: 10.1093/schbul/sbaa028.063
Abstract: Abstract Background The synaptic dysfunction hypothesis of schizophrenia is supported by multiple lines of evidence. However, in vivo evidence is lacking. Moreover, it is not known if antipsychotics alter synaptic protein levels. We addressed this…
read more here.
Keywords:
protein;
sv2a;
group;
scz cohen ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Neurochemistry"
DOI: 10.1111/jnc.16186
Abstract: Following exocytosis, the recapture of plasma membrane‐stranded vesicular proteins into recycling synaptic vesicles (SVs) is essential for sustaining neurotransmission. Surface clustering of vesicular proteins has been proposed to act as a ‘pre‐assembly’ mechanism for endocytosis…
read more here.
Keywords:
syt1 synaptic;
recruitment;
sv2a;
syt1 ... See more keywords
Sign Up to like & get
recommendations!
3
Published in 2023 at "Neurobiology of Aging"
DOI: 10.2139/ssrn.4297860
Abstract: Histological and biochemical analyses in postmortem tissues have demonstrated neurodegenerative changes in the cerebral cortex in patients with Alzheimer's disease (AD), and it has been suggested that this represents a loss of synapses. PET imaging…
read more here.
Keywords:
cerebral cortex;
alzheimer disease;
patients alzheimer;
cortex ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Frontiers in Aging Neuroscience"
DOI: 10.3389/fnagi.2024.1380561
Abstract: This manuscript presents a thorough review of synaptic vesicle glycoprotein 2A (SV2A) as a biomarker for synaptic integrity using Positron Emission Tomography (PET) in neurodegenerative diseases. Synaptic pathology, characterized by synaptic loss, has been linked…
read more here.
Keywords:
pet imaging;
sv2a pet;
human neurodegenerative;
sv2a ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Molecular Neuroscience"
DOI: 10.3389/fnmol.2022.881933
Abstract: Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam. Although several rodent knockout models have demonstrated the importance of…
read more here.
Keywords:
connectivity;
epileptic drug;
sv2a;
epilepsy ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1066447
Abstract: Background: Current treatments for progressive neurodegenerative disorders characterized by cognitive impairment either have limited efficacy or are lacking altogether. SDI-118 is a small molecule which modulates the activity of synaptic vesicle glycoprotein 2A (SV2A) in…
read more here.
Keywords:
sdi 118;
target engagement;
brain;
sv2a ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Biomolecules"
DOI: 10.3390/biom12121821
Abstract: Botulinum neurotoxins are the deadliest microbial neurotoxins in humans, with a lethal dose of 1 ng/kg. Incidentally, these neurotoxins are also widely used for medical and cosmetic purposes. However, little is known about the molecular…
read more here.
Keywords:
bont;
glycosylated human;
toxin;
type ... See more keywords